Search
Dimethylthiambutene
go.drugbank.com/drugs/DB01444ExperimentalIllicitIt is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.
Synonyms: N,N-dimethyl-4,4-di(2-thienyl)-3-buten-2-amineAN0128
go.drugbank.com/drugs/DB05054InvestigationalOf particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents. … AN0128 has broad spectrum activity against a wide variety of Gram positive bacteria, including many that are known skin colonizers.
RUS 3108
go.drugbank.com/drugs/DB05911ExperimentalRUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories. … The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
AG0301-COVID19
go.drugbank.com/drugs/DB15856InvestigationalOn September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472). … The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product.
Tegoprazan
go.drugbank.com/drugs/DB16690Investigational[A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels. … [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.
Products: KI-CAB® TABLETAS 50 MGFolitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
SL017
go.drugbank.com/drugs/DB05156ExperimentalSL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Surotomycin
go.drugbank.com/drugs/DB12076InvestigationalDifficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. … Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection.
Patupilone
go.drugbank.com/drugs/DB03010InvestigationalEpothilone B is a 16-membered macrolide that mimics the biological effects of taxol.